Emcure Pharmaceuticals Ltd
NSE:EMCURE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
905.6
1 504.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
EMCURE Price Targets Summary
Emcure Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for EMCURE is 1 696.77 INR with a low forecast of 1 565.5 INR and a high forecast of 1 837.5 INR.
Operating Income
Forecast
Operating Income Estimate
Emcure Pharmaceuticals Ltd
For the last 2 years the compound annual growth rate for Emcure Pharmaceuticals Ltd's operating income is 9%. The projected CAGR for the next 3 years is 22%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is EMCURE's stock price target?
Price Target
1 696.77
INR
According to Wall Street analysts, the average 1-year price target for EMCURE is 1 696.77 INR with a low forecast of 1 565.5 INR and a high forecast of 1 837.5 INR.
What is Emcure Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
13%
For the last 2 years the compound annual growth rate for Emcure Pharmaceuticals Ltd's revenue is 15%. The projected CAGR for the next 3 years is 13%.
What is Emcure Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
22%
For the last 2 years the compound annual growth rate for Emcure Pharmaceuticals Ltd's operating income is 9%. The projected CAGR for the next 3 years is 22%.
What is Emcure Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
27%
For the last 2 years the compound annual growth rate for Emcure Pharmaceuticals Ltd's net income is 13%. The projected CAGR for the next 3 years is 27%.
